MedTrace Logo

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

NCT04460105 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-10-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, pharmacokinetic and pharmacodynamics of lanadelumab administered by intravenous (IV) infusion when added to standard-of-care (SoC) in adults hospitalized with COVID-19 pneumonia.

Conditions

Interventions

DRUG

Lanadelumab

Participants will receive 300 mg of lanadelumab IV infusion on Day 1 and Day 4.

OTHER

Placebo

Participants will receive placebo matching IV infusion on Day 1 and Day 4.

Sponsors & Collaborators

  • Takeda Development Center Americas, Inc.

    collaborator INDUSTRY

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda Development Center Americas, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2021-01-27
Completion
2021-01-27
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04460105 on ClinicalTrials.gov